CN105051188A - 新颖方法 - Google Patents

新颖方法 Download PDF

Info

Publication number
CN105051188A
CN105051188A CN201380070275.6A CN201380070275A CN105051188A CN 105051188 A CN105051188 A CN 105051188A CN 201380070275 A CN201380070275 A CN 201380070275A CN 105051188 A CN105051188 A CN 105051188A
Authority
CN
China
Prior art keywords
cell
cells
tet3
gene
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380070275.6A
Other languages
English (en)
Chinese (zh)
Inventor
W.赖克
J.皮特
T.霍尔
C.克鲁格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Babraham Institute
Original Assignee
Babraham Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Babraham Institute filed Critical Babraham Institute
Publication of CN105051188A publication Critical patent/CN105051188A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
CN201380070275.6A 2012-12-17 2013-12-17 新颖方法 Pending CN105051188A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1222693.2 2012-12-17
GBGB1222693.2A GB201222693D0 (en) 2012-12-17 2012-12-17 Novel method
PCT/GB2013/053317 WO2014096800A1 (en) 2012-12-17 2013-12-17 Novel method

Publications (1)

Publication Number Publication Date
CN105051188A true CN105051188A (zh) 2015-11-11

Family

ID=47630838

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380070275.6A Pending CN105051188A (zh) 2012-12-17 2013-12-17 新颖方法

Country Status (8)

Country Link
US (2) US20160186207A1 (https=)
EP (1) EP2931881A1 (https=)
JP (2) JP2016500260A (https=)
CN (1) CN105051188A (https=)
AU (1) AU2013366092A1 (https=)
CA (1) CA2894822A1 (https=)
GB (1) GB201222693D0 (https=)
WO (1) WO2014096800A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020513832A (ja) * 2017-03-22 2020-05-21 ノバルティス アーゲー 免疫腫瘍学のための組成物および方法
US12037583B2 (en) 2015-12-04 2024-07-16 Novartis Ag Compositions and methods for immunooncology

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037001A2 (en) 2008-09-26 2010-04-01 Immune Disease Institute, Inc. Selective oxidation of 5-methylcytosine by tet-family proteins
ES2609845T3 (es) 2011-07-29 2017-04-24 Cambridge Epigenetix Limited Métodos para la detección de modificación de nucleótidos
ES2669512T3 (es) 2012-11-30 2018-05-28 Cambridge Epigenetix Limited Agente oxidante para nucleótidos modificados
GB201403216D0 (en) 2014-02-24 2014-04-09 Cambridge Epigenetix Ltd Nucleic acid sample preparation
CN104630272A (zh) * 2015-01-06 2015-05-20 西北农林科技大学 一种基于去甲基化促进生殖干细胞自我更新和增殖的载体及其应用
WO2018073787A2 (en) * 2016-10-19 2018-04-26 Fred Hutchinson Cancer Research Center Compositions and methods for reprogramming cells and for somatic cell nuclear transfer using duxc expression
SG11201909866VA (en) * 2017-05-29 2019-11-28 Agency Science Tech & Res Markers of totipotency and methods of use
WO2019164876A1 (en) * 2018-02-20 2019-08-29 The Regents Of The University Of California Therapeutics that invoke epigenetic changes for use in treating neurological conditions such as cognitive impairment
US11939593B2 (en) 2018-08-01 2024-03-26 University Of Georgia Research Foundation, Inc. Compositions and methods for improving embryo development

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101356270A (zh) * 2005-12-13 2009-01-28 国立大学法人京都大学 核重新编程因子
US20110236894A1 (en) * 2008-09-26 2011-09-29 Immune Disease Institute, Inc. Selective oxidation of 5-methylcytosine by tet-family proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101356270A (zh) * 2005-12-13 2009-01-28 国立大学法人京都大学 核重新编程因子
US20110236894A1 (en) * 2008-09-26 2011-09-29 Immune Disease Institute, Inc. Selective oxidation of 5-methylcytosine by tet-family proteins

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
D.B.B.P. PARIS等: "Equine embryos and embryonic stem cells:Defining reliable markers of pluripotency", 《THERIOGENOLOGY》 *
LAKSHMINARAYAN M. IYER等: "Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids", 《CELL CYCLE》 *
SHANBO CAO等: "Isolation and Culture of Primary Bovine Embryonic Stem Cell Colonies by a Novel Method", 《JOURNAL OF EXPERIMENTAL ZOOLOGY》 *
SHINSUKE ITO等: "Role of Tet proteins in 5mC to 5hmC conversion,ES-cell self-renewal and inner cell mass specification", 《NATURE》 *
T.A.L. BREVINI等: "No shortcuts to pig embryonic stem cells", 《THERIOGENOLOGY》 *
YUFEI XU等: "Tet3 CXXC Domain and Dioxygenase Activity Cooperatively Regulate Key Genes for Xenopus Eye and Neural Development", 《CELL》 *
张燕霞等: "5-羟甲基胞嘧啶的研究进展", 《遗传》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12037583B2 (en) 2015-12-04 2024-07-16 Novartis Ag Compositions and methods for immunooncology
JP2020513832A (ja) * 2017-03-22 2020-05-21 ノバルティス アーゲー 免疫腫瘍学のための組成物および方法
US11851659B2 (en) 2017-03-22 2023-12-26 Novartis Ag Compositions and methods for immunooncology

Also Published As

Publication number Publication date
US20190264223A1 (en) 2019-08-29
JP2016500260A (ja) 2016-01-12
GB201222693D0 (en) 2013-01-30
EP2931881A1 (en) 2015-10-21
WO2014096800A1 (en) 2014-06-26
CA2894822A1 (en) 2014-06-26
JP2019058176A (ja) 2019-04-18
US20160186207A1 (en) 2016-06-30
AU2013366092A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
US20190264223A1 (en) Novel method
Jaenisch et al. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming
Gafni et al. Derivation of novel human ground state naive pluripotent stem cells
JP2025106394A (ja) 多能性細胞のデノボ生成
EP2989199B1 (en) Isolated naive pluripotent stem cells and methods of generating same
JP6257520B2 (ja) 人工多能性幹細胞または分化細胞を作製するための自動化されたシステム
JP2021520215A (ja) リプログラミングベクター
US20230392125A1 (en) Methods for generating formative pluripotent stem cells competent for direct primordial germ cell induction
Nowak-Imialek et al. Oct4-enhanced green fluorescent protein transgenic pigs: a new large animal model for reprogramming studies
JP2023553932A (ja) ウーリーマンモス対立遺伝子を用いる遺伝子編集のための組成物および方法
CN104884612A (zh) Mait样细胞及其制作方法
Lee et al. Blastomere aggregation using phytohemagglutinin-L improves the establishment efficiency of porcine parthenogenesis-derived embryonic stem-like cell lines
WO2013181641A1 (en) Totipotent stem cells
US20130102479A1 (en) Methods of enhancing pluripotentcy
US11859213B2 (en) Development of superior chimerism by hiPSC engineering and embryo aggregation
US20210284960A1 (en) Method of generating hepatic cells
Villafranca Locher Fusion of bovine fibroblasts to mouse embryonic stem cells: a model to study nuclear reprogramming
شذى الإيمان خالد محمد صوالحة X Chromosome Inactivation Patterns in Human Induced Pluripotent Stem Cells (hiPSC)
Ajduk Session 5. Stem Cells and Regenerative Medicine
Reinholt Conversion of equine umbilical cord matrix mesenchymal stem cells to the trophectoderm lineage using the Yamanaka reprogramming factors
Palecek Pluripotent stem cells: Sources and characterization
Dénommé Induced pluripotent stem cells: where are we today?
Parenti Making mammalian stem cells: Identifying and overcoming reprogramming barriers
De Lazaro Del Rey In vivo cell reprogramming to pluripotency: generating induced pluripotent stem cells in situ for tissue regeneration
Mahaddalkar Reprogramming hierarchy in mouse liver cell subpopulations depends on cell intrinsic factors including BAF complex members

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20151111